Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study
Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study have?
Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study has 41 citations in the OpenAlex counts ScholarIQ stores.
When was Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study published?
Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study has 2019 year in the ScholarIQ index.
What is the open-access status of Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study?
Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study has hybrid oa status in the ScholarIQ index.
What is the DOI of Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study?
The DOI for Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study is on the source record.
What is the PMID of Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study?
The PMID for Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study is on the source record.
What is the OpenAlex record for Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study?
The OpenAlex for Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study is on the source record.